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Adenosine triphosphate (ATP) is released by bacteria and host cells during bacterial 
infection as well as sterile tissue injury, acting as an inducer of inflammasome activation. 
Previous studies have shown that ATP treatment leads to AMP-activated protein kinase 
(AMPK) activation. However, it is unclear whether AMPK signaling has been involved 
in the regulation of ATP-induced inflammasome activation and subsequent pyroptosis. 
In this study, we aimed to investigate this issue in lipopolysaccharide-activated murine 
macrophages. Our results showed that AMPK signaling was activated in murine macro-
phages upon ATP treatment, which was accompanied by inflammasome activation and 
pyroptosis as evidenced by rapid cell membrane rupture as well as mature interleukin 
(IL)-1β and active caspase-1p10 release. The ATP-induced inflammasome activation and 
pyroptosis were markedly suppressed by an AMPK inhibitor compound C or small-in-
terfering RNA-mediated knockdown of AMPKα, but could be greatly enhanced by met-
formin (a well-known AMPK agonist). Importantly, metformin administration increased 
the mortality of mice with bacterial sepsis, which was likely because metformin treatment 
enhanced the systemic inflammasome activation as indicated by elevated serum and 
hepatic IL-1β levels. Collectively, these data indicated that the AMPK signaling positively 
regulated ATP-induced inflammasome activation and pyroptosis in macrophages, high-
lighting the possibility of AMPK-targeting therapies for inflammatory diseases involving 
inflammasome activation.
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inTrODUcTiOn
Inflammasomes are large multimeric protein complexes present in the cytosol of immune cells to 
sense and respond to pathogen infection or tissue injury. Their activation constitutes a first line of 
defense against microbial infection (1). One of the most extensively investigated inflammasomes 
is nucleotide and oligomerization domain, leucine-rich repeat containing protein family, pyrin 
containing domain 3 (NLRP3) in innate immune cells including macrophages. The full activa-
tion of NLRP3 inflammasome requires two steps. The first step is to prime the macrophages with 
pathogen-associated molecular patterns (PAMPs) which are recognized by specific pattern recogni-
tion receptors (PRRs) (2). For example, lipopolysaccharide (LPS), a well-known PAMP expressed 
on Gram-negative bacteria, binds to and activates toll-like receptor 4 leading to the upregulation 
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of critical inflammasome components (e.g., NLRP3 protein) (3). 
The second step is to trigger these primed cells by danger signals, 
such as adenosine triphosphate (ATP) and uric acid crystal, 
culminating in the assembly of NLRP3 inflammasome (1). This 
is the canonical pathway of NLRP3 inflammasome activation. 
Recently, it has been demonstrated that LPS can directly bind to 
and activate caspase-11 when LPS is released into the cytosol from 
engulfed bacteria via as-yet-unrecognized routes or by artificial 
transfection into the cytosol (4), which subsequently leads to the 
non-classical NLRP3 inflammasome activation (3, 5).
Following the assembly of inflammasomes, intracellular 
caspase-1 is activated to catalyze pro-interleukin-1β (pro-IL-
1β) cleavage into mature IL-1β (1). As a canonical activator of 
NLRP3 inflammasome, ATP can be released from both host 
and bacterial cells in the circumstance of bacterial infection (6) 
or tissue injury (7, 8). Upon PAMP stimulation, monocytes/
macrophages can release endogenous ATP into the extracellular 
milieu (8), and they can also produce carbon monoxide (CO) 
to promote bacterial ATP release, resulting in the activation of 
NLRP3 inflammasome and maturation of IL-1β to intensify 
bacterial killing (9). Notably, the release of mature IL-1β is reli-
ant on pyroptosis (10). Pyroptosis is another consequence of 
caspase-1 activation, which is characterized by rapid cell swelling 
and membrane rapture, leading to the release of intracellular 
contents (11). Therefore, inflammasome activation represents 
robust inflammatory responses during bacterial infection or tis-
sue injury, which should benefit the host to clear the pathogens 
or repair the injured tissues by recruiting various inflammatory 
immune cells. However, sustained inflammasome activation by 
endogenous danger signals released from damaged cells may 
aggravate the pathological inflammation in sterile inflammatory 
disorders (12–14). It has been demonstrated that inflammasome 
activation and pyroptosis can also take place in multiple organs 
after systemic infection (sepsis) (15, 16), implicating pyroptosis as 
one cause of multiple organ failure in septic patients (3).
Although NLRP3 inflammasome activation has a critical role 
in bacterial infection or other pathological conditions, the sign-
aling pathways regulating this process are still elusive. The fact 
that septic patients usually require nutrition supplement in clinic 
suggests that energy metabolism may influence cell survival in 
sepsis (17). Among the regulators of cellular energy metabolism, 
AMP-activated protein kinase (AMPK) is a key nexus highly 
conserved in eukaryotic cells for sensing and responding to cel-
lular energy status (18). It is a heterotrimeric protein comprised 
of α, β, and γ subunits, and the α subunit contains the catalytic 
domain, in which phosphorylation at threonine (Thr) 172 makes 
this kinase activated (19). The activation of AMPK takes place 
when the cellular AMP/ATP ratio is elevated due to metabolic 
stresses (e.g., insufficient glucose and oxygen supply) or ATP 
consumption (e.g., muscle contraction). It regulates not only 
cellular metabolism but also cell survival and proliferation (20). 
Therefore, we hypothesized that AMPK might have been involved 
in the regulation of ATP-induced inflammasome activation and 
pyroptosis. Indeed, recent studies have indicated that bacterial 
infection or ATP treatment in LPS-primed macrophages can 
dramatically elevate AMPK activation, although LPS per se sup-
presses the activity of AMPK (21–23).
In this study, we aimed to investigate whether AMPK activa-
tion contributed to ATP-induced inflammasome activation in 
LPS-primed murine macrophages. Our results demonstrated 
that enhancing AMPK activation by metformin (an agonist 
of AMPK) sensitized LPS-primed macrophages to pyroptosis 
upon ATP treatment, while suppression of AMPK activity by 
its pharmacologic inhibitor compound C or AMPKα-specific 
small-interfering RNA (siRNA) reduced the ratio of pyroptosis. 
Moreover, metformin administration to mice significantly 
increased the systemic levels of IL-1β and animal mortality upon 
bacterial infection. Our data indicated that AMPK signaling had 
been involved in ATP-induced inflammasome activation and 
pyroptosis in LPS-primed macrophages.
MaTerials anD MeThODs
reagents and animals
DMEM, Opti-MEM, l-glutamine, streptomycin, penicillin, and 
fetal bovine serum (FBS) were obtained from Thermo/Fisher/
Gibco (Carlsbad, CA, USA). LPS (Escherichia coli O111:B4) 
(L4391), ATP (P8232), dimethyl sulfoxide, Hoechst 33342, 
propidium iodide (PI), Tween-80, and compound C were 
bought from Sigma-Aldrich (St. Louis, MO, USA). Metformin 
was obtained from MedChem Express (Princeton, NJ, USA), 
dissolved in PBS at 300 mM and stored at −20°C. The working 
solution of metformin was freshly prepared. Antibodies against 
IL-1β (#12242), HMGB1 (#3935), AMPKα (#5832), phospho(p)-
AMPK (Thr172) (#2535), β-tubulin (#2128), ASC (#67824), and 
horseradish peroxidase-conjugated goat anti-mouse/rabbit IgG 
were bought from Cell Signaling Technology (Danvers, MA, 
USA). The antibody to NLRP3 (AG-20B-0014) was purchased 
from Adipogen AG (Liestal, Switzerland). The antibody against 
caspase-1p10 (sc-514) was obtained from Santa Cruz (Santa 
Cruz Biotechnology, Dallas, TX, USA). Anti-mouse CD11b 
FITC (11-0112) and anti-mouse Ly-6G (Gr-1) PE (12-9668) were 
obtained from eBioscience (San Diego, CA, USA). C57BL/6 mice 
(6–8 weeks of age) were purchased from the Laboratory Animal 
Center of Southern Medical University (Guangzhou, China). All 
animal experiments were performed according to the guidelines 
for the care and use of animals approved by the Committee on the 
Ethics of Animal Experiments of Jinan University.
cell line culture
Mouse macrophage cell line J774A.1 was obtained from the 
Kunming Cell Bank of Type Culture Collection Chinese Academy 
of Sciences (Kunming, China). The cells were maintained in com-
plete DMEM medium (containing 10% FBS, 100 µg/ml penicillin, 
100 µg/ml streptomycin, and 2 mM l-glutamine) and cultured 
at 37°C in a humidified incubator with 5% CO2. The cells were 
subcultured every 2–3 days.
Bone Marrow-Derived  
Macrophages (BMDMs)
Bone marrow-derived macrophages from C57BL/6 mice were 
differentiated as reported previously (3). Briefly, mouse bone 
marrow cells were differentiated in DMEM supplemented with 
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10% FBS and 20% M-CSF-conditioned medium from L929 cells 
for 6 days. The BMDMs were then cultured overnight in 24-well 
plates at 1.8 × 105 cells/well in 0.5 ml medium.
Determination of soluble cytokines
Soluble IL-1β in cell culture medium and orbital serum were 
determined by cytometric bead array (CBA) mouse IL-1β flex 
set (#560232) according to the manufacturer’s instructions (BD 
Biosciences, San Jose, CA, USA).
Phenotype analysis
Cells were washed twice with PBS-F (PBS containing 0.1% NaN3 
and 3% FBS), then stained with FITC-labeled anti-CD11b and 
PE-labeled anti-mouse Ly-6G monoclonal antibodies for 30 min. 
Red blood cells, if there were, were lysed. After washing with PBS-
F, the cells were fixed with 4% paraformaldehyde in PBS and then 
analyzed by a flow cytometer (FACSCalibur; Becton Dickinson).
Pyroptosis assay
Cell pyroptosis was measured as described previously (24, 25). 
Briefly, cells were seeded in 24-well plates and cultured for 24 h. 
The cells were then primed with 500 ng/ml LPS for 4 h followed 
by treatment with indicated concentrations of metformin in 
Opti-MEM for 1  h. Next, indicated concentrations of ATP 
were added to the culture medium for indicated time periods. 
Subsequently, the cells were stained with staining solution con-
taining PI (2 µg/ml) and Hoechst 33342 (5 µg/ml). Dead cells 
(PI permeable) were observed under a Zeiss Axio Observer D1 
microscope and fluorescence images were captured by the Zeiss 
AxioCam MR R3 cooled CCD camera controlled with ZEN 
software (ZEISS, Germany).
Precipitation of soluble Proteins
Precipitation of soluble proteins was performed as previously 
described (26). In brief, proteins existing in cell culture super-
natants were precipitated overnight with 7.2% trichloroacetic 
acid and 0.15% sodium deoxycholate solutions. After washing 
three times with cold acetone, the precipitated proteins were 
redissolved in sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) loading buffer and subjected to western 
blot analysis.
Western Blot analysis
Whole cell lysates and western blotting were performed as previ-
ously described (27). Cells were lysed with 2× SDS-PAGE loading 
buffer, and the total proteins were separated by SDS-PAGE and 
then transferred onto polyvinylidene difluoride membranes 
(Hybond-P; GE Healthcare Life Sciences, Piscataway, NJ, 
USA). The membrane was blocked and incubated with primary 
antibody overnight, followed by incubation with horseradish 
peroxidase-conjugated goat anti-rabbit IgG or goat anti-mouse 
IgG. Bands on the membrane were revealed by a BeyoECL Plus 
kit (Beyotime, P0018) and recorded on X-ray films (Kodak, 
6535873). Images were captured by using FluorChem 8000 
Imaging System (AlphaInnotech, San Leandro, CA, USA), and 
densitometry of each band was quantified using AlphaEaseFC 
software (AlphaInnotech).
immunofluorescence Microscopy
Bone marrow-derived macrophages were planted in glass-bottomed 
dishes (5 × 105 cells/dish) and cultured at 37°C overnight. Then the 
cells were primed with 500 ng/ml LPS for 4 h, followed by treatment 
with 2 mM metformin or vehicle (PBS) for 1 h. Subsequently, 2 mM 
ATP was added to the culture medium for 30 min. After these treat-
ments, the cells were fixed in 4% paraformaldehyde for 15 min and 
permeabilized with 2 ml cold methanol (−20°C) for 10 min. Then 
the cells were incubated with ASC antibody (1:300) overnight, 
followed by staining with CF568-conjugated goat-anti-rabbit IgG 
(#20103) (Biotium, Hayward, CA, USA) for 1 h. Finally, Hoechst 
33342 solution (5 µg/ml in PBS) was added to stain the nuclei for 
10 min. The cells were observed under a Zeiss Axio Observer D1 
microscope with a Zeiss LD Plan-Neofluar 40×/0.6 Korr M27 
objective (Carl Zeiss MicroImaging GmbH, Göttingen, Germany). 
Fluorescence images were captured with a Zeiss AxioCam MR R3 
cooled CCD camera controlled with ZEN software (ZEISS).
Knockdown of aMPKα
The siRNA (5′-GCA GAA GUG UGU AGA GCA A-3′) duplexes 
targeting mouse AMPKα1 and negative control (NC) siRNA 
were designed and synthesized by RiboBio (Guangzhou, China). 
Knockdown of AMPKα1 was performed according to the 
instructions provided by the manufacturers. Briefly, transfection 
reagent Lipofectamine RNAiMAX (Invitrogen, 13778-075) and 
AMPKα1 siRNA were diluted in Opti-MEM, respectively, and 
then mixed together. The NC siRNA mixture was also prepared. 
Then the cell culture medium was replaced with Opti-MEM, and 
the siRNA mixture was added at a final siRNA concentration of 
100 nM. Six hours later, the cells were cultured in normal medium 
containing 10% FBS. After being cultured for additional 72 h, the 
cells were ready for experiments.
Bacterial infection
Bacterial sepsis mouse model was established as previously 
described (9, 27). Briefly, C57BL/6 mice were acclimated for 
1 week. Bacteria (E. coli DH5α) were cultured and proliferated in 
Luria Broth medium. Then the viable bacteria were resuspended 
in PBS at 2 ×  109  CFU/ml. Each mouse was intraperitoneally 
injected with 0.5 ml bacterial suspension. Metformin (dissolved 
in PBS) or vehicle (PBS) was given intragastrically 1 h later at a 
dose of 250 mg/kg body weight for once. The mice were given 
ad libitum access to drinking water or water containing 1.5 mg/ml 
metformin. Mouse survival was monitored every 6 h for 4 days.
histopathology
Mice were sacrificed 8 h after bacterial infection. The liver was 
harvested, fixed in 4% neutral formaldehyde. Paraffin slice of 
the liver was stained with hematoxylin and eosin. Images were 
captured under the Zeiss Axio Observer D1 microscope armed 
with a color CCD (ZEISS).
statistical analysis
All experiments were performed independently at least three 
times unless otherwise stated, with one representative experiment 
shown. Data are presented as mean ± SD. Statistical analysis was 
performed using GraphPad Prism 4.0 (GraphPad; San Diego, CA, 
FigUre 1 | Metformin enhanced adenosine triphosphate (aTP)-induced pyroptosis in lipopolysaccharide (lPs)-activated macrophages. Mouse bone 
marrow-derived macrophages (a,B) and J774A.1 cells (c,D) were first primed with LPS (500 ng/ml) for 4 h, followed by treatment with indicated concentrations of 
metformin for 1 h. Subsequently, 2 mM ATP (a) or 3 mM ATP (c) was added to the medium for 30 min. Cells were stained by Hoechst 33342 (blue; for all cells) and 
propidium iodide (red; for pyroptotic cells) and images were captured using fluorescence microscopy, merged with bright-field images. Five independent 
experiments were performed (each in triplicates), and representative data from one experiment are shown. (B,D) Pyroptosis of five random fields each containing 
about 100 cells was calculated. Data are shown as mean ± SD (n = 5). Scale bars, 50 µm. Met, metformin. **P < 0.01; ***P < 0.001; and ns, not significant.
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USA). One-way analysis of variance followed by Tukey’s multiple 
comparison test was used to analyze the statistical significance 
among multiple groups and unpaired Student’s t-test between 
two groups. Kaplan–Meier survival curves were adopted for 
analysis of mice survival, and the statistical difference between 
two groups was determined using the log-rank (Mantel–Cox) 
test. P values < 0.05 were considered statistically significant.
resUlTs
aMPK agonist Metformin enhances  
aTP-induced Pyroptosis in Macrophages
Although many studies have focused on how inflammasomes 
are assembled and activated, little is known about the regulatory 
signaling of NLRP3 inflammasome activation upon extracellular 
ATP stimulation. As dramatic metabolic changes occur during 
macrophage activation (22), it is of great interest whether AMPK, 
a key regulator of energy metabolism, regulates ATP-induced 
inflammasome activation in LPS-primed macrophages. To 
explore this problem, LPS-activated BMDMs were treated with 
serial concentrations of metformin, a well-known AMPK agonist, 
followed by ATP treatment. First, we observed the pyroptotic cells 
(PI permeable) and calculated their ratio to the total cells (indi-
cated by nuclear dye Hoechst 33342). As expected, ATP induced 
pyroptosis in the BMDMs; and metformin treatment further 
increased the pyroptosis induced by LPS and ATP treatment 
(Figures 1A,B). However, metformin alone did not induce cell 
death in both control and LPS-treated cells without ATP treatment 
(Figure S1A in Supplementary Material). Similar results were 
FigUre 2 | Metformin increased adenosine triphosphate-induced inflammasome activation in bone marrow-derived macrophages. (a) Cells were 
treated as described in Figure 1. Indicated protein levels in both cell lysates and supernatants were evaluated by western blotting. β-Tubulin was used as a loading 
control for cell lysates. (B–D) The quantitative analyses of the active caspase-1p10 (B), mature interleukin-1β (c), and HMGB1 (D) levels in the supernatants (a) are 
shown. Data are shown as mean ± SD (n = 3). One representative experiment from three independently performed experiments with similar results is shown. 
*P < 0.05; **P < 0.01; and ***P < 0.001.
5
Zha et al. AMPK Regulates Inflammasome Activation and Pyroptosis
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 597
observed in mouse macrophage J774A.1 cell line (Figures 1C,D; 
Figure S1B in Supplementary Material). Considering that met-
formin is an AMPK agonist, these results suggested that AMPK 
signaling might have contributed to ATP-induced pyroptosis in 
LPS-activated macrophages.
aMPK signaling is suppressed by  
lPs but reactivated by extracellular aTP
It has been observed that the activity of AMPK can be dampened 
in macrophages by LPS, free fatty acid, or other stimulators (28). 
But recent studies showed that AMPK signaling is dramatically 
increased in LPS-activated macrophages after ATP treatment 
(21, 22), accompanied by pyroptosis and mature IL-1β release 
(22). Consistent with these studies, western blot analysis dem-
onstrated that LPS (alone) treatment led to a marked increase 
of NLRP3 and pro-IL-1β protein expression in BMDMs, but 
it did not induce the release of active caspase-1p10, mature 
IL-1β, and HMGB1 (Figures 2A–D, supernatants). Upon ATP 
triggering, however, active caspase-1p10 fragment, HMGB1, 
and mature IL-1β (17 kDa) were released into the supernatants 
(Figures 2A–D). Moreover, the release of these contents from 
FigUre 3 | Metformin treatment increased adenosine triphosphate (aTP)-induced asc speck formation and interleukin (il)-1β secretion in bone 
marrow-derived macrophages (BMDMs). (a) Mouse BMDMs were seeded in glass-bottomed dishes and primed with lipopolysaccharide (500 ng/ml, in 
complete DMEM medium) for 4 h, and then treated with metformin (2 mM, in Opti-MEM) for 1 h. Subsequently, 2 mM ATP was added to the medium for 30 min. 
The distribution of ASC (red) was revealed by immunofluorescence microscopy with the nuclei being stained with Hoechst 33342 (blue). The images for ASC and 
nuclei were captured, respectively, and merged together. The experiment was performed twice, with one representative set of images shown. The yellow arrows 
indicate ASC specks. An enlarged inset for each image with an ASC speck is also shown. Scale bar, 20 µm; Met, metformin. (B) The ratios of cells containing ASC 
specks were calculated by the number of cells with ASC specks relative to the total number of cells from five random fields each containing about 50 cells. Data are 
shown as mean ± SD (n = 5). (c) Quantification of soluble IL-1β levels in the cell culture supernatants by cytometric bead array assay. Data are shown as 
mean ± SD (n = 3). ***P < 0.001.
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the cells in response to ATP stimulation can be further promoted 
by metformin treatment (Figures  2A–D). As the release of 
mature IL-1β is dependent on pyroptosis (4, 10), our results sug-
gested that the augmentation of AMPK signaling by metformin 
enhanced LPS +  ATP-induced inflammasome activation and 
pyroptosis.
Next, we performed two additional assays to corroborate the 
augmentation effect of metformin on ATP-induced inflamma-
some activation. First, the subcellular distribution of ASC in 
BMDMs was observed by immunofluorescence microscopy. 
ASC is an adaptor protein that mediates the recruitment of 
caspase-1 to the NLRP3 inflammasome to form a large speck 
in the cell, and thus activates caspase-1 (29). The results showed 
that ASC was evenly distributed in LPS and vehicle-treated 
BMDMs (Figure 3A). After ATP treatment, ASC specks could 
be observed in ~20% of LPS-primed cells (Figures  3A,B), 
indicating the activation of inflammasomes as having been 
indicated previously (30). Furthermore, metformin treatment 
increased the ratio of cells containing ASC specks induced by 
ATP to >40% (Figures 3A,B). Second, the CBA assay was used 
to detect soluble IL-1β in the supernatants. The results showed 
that LPS + ATP treatment induced a significant release of IL-1β 
from BMDMs, which could be greatly promoted by metformin 
treatment (Figure 3C).
In J774A.1 cells, we also observed that LPS induced the expres-
sion of NLRP3 and pro-IL-1β (Figure  4A, cell lysates). Upon 
ATP treatment, both active caspase-1p10 and HMGB1 could be 
released into the supernatants, and metformin dose-dependently 
increased their release (Figures 4A–C). Although soluble IL-1β 
was hardly detectable in the precipitated proteins of the culture 
FigUre 4 | Metformin enhanced adenosine triphosphate-induced inflammasome activation in J774a.1 cells. (a) Cells were treated as described in 
Figure 1. Indicated protein levels in both cell lysates and supernatants were evaluated by western blotting. β-Tubulin was used as a loading control for cell lysates. 
(B,c) Quantitative analyses of active caspase-1p10 (B) and HMGB1 (c) levels in the supernatants (a). (D) Quantification of soluble interleukin-1β levels in the cell 
culture supernatants by cytometric bead array assay. Data are shown as mean ± SD (n = 3). One representative experiment from three independently performed 
experiments with similar results is shown. *P < 0.05; **P < 0.01; and ***P < 0.001.
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supernatants by western blotting, CBA assays could detect such 
low levels of IL-1β and the result showed that LPS + ATP induced 
the release of IL-1β and metformin dose-dependently enhanced 
its release (Figure 4D).
It seemed that metformin did not influence the constitutive 
expression of pro-caspase-1 (45 kDa) and the induced-expression 
of pro-IL-1β (31 kDa) and NLRP3 (120 kDa) by LPS in the two 
cell types, nor did it induce the release of mature IL-1β, active 
caspase-1p10, and HMGB1 as well as the formation of ASC 
specks in the absence of ATP treatment (Figures 2–4).
Interestingly, in BMDMs, AMPK activity (reflected by its 
phosphorylation at Thr172) was suppressed by LPS alone 
(Figures 5A,B); while in J774A.1 cells, AMPK activity was low in 
both control and LPS (alone) groups (Figures 5C,D). Upon ATP 
treatment, however, AMPK was reactivated in both cell types. 
Furthermore, metformin treatment dose-dependently increased 
the AMPK activation as compared to their respective control 
(LPS alone or LPS + ATP) (Figures 5A–D).
Altogether, these results suggested that elevated AMPK signal-
ing was associated with inflammasome activation and pyroptosis 
in LPS-primed macrophages upon ATP stimulation.
suppression of aMPK signaling 
attenuates Pyroptosis in Macrophages
To further explore whether AMPK activation contributes 
to ATP-induced pyroptosis in LPS-activated macrophages, 
BMDMs were first primed with LPS and then treated with 
FigUre 5 | Metformin enhanced adenosine triphosphate-induced aMP-activated protein kinase (aMPK) signaling in bone marrow-derived 
macrophages [BMDMs, (a,B)] and J774a.1 cells (c,D). (a,c) BMDMs and J774A.1 cells were treated as described in Figure 1, respectively. Indicated protein 
levels of p-AMPKα and AMPKα were evaluated by western blotting. β-Tubulin was used as a loading control for cell lysates. (B,D) Quantification of p-AMPKα levels 
relative to AMPKα in BMDMs (B) and J774A.1 cells (D). Data are shown as mean ± SD (n = 3). One representative experiment from three independently performed 
experiments with similar results is shown. *P < 0.05; **P < 0.01; ***P < 0.001; and ns, not significant.
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compound C, a well-known pharmacological AMPK inhibitor 
(31, 32). Subsequently, the cells were treated with ATP. As shown 
in Figures 6A,B, compound C significantly suppressed ATP-
induced pyroptosis in LPS-primed BMDMs. Supporting this, 
compound C also inhibited the release of IL-1β (Figure 6C) 
and the formation of ASC specks (Figures 6D,E) in these cells. 
Similar results were observed in J774A.1 cells. Compound C 
not only suppressed ATP-induced pyroptosis (Figures 7A,B) 
but also inhibited the secretion of IL-1β (Figure  7C) and 
HMGB1 (Figure  7D) from J774A.1 cells. Moreover, com-
pound C significantly attenuated the effect of metformin 
on promoting ATP-induced pyroptosis (Figures  6A,B and 
7A,B), as well as the release of IL-1β (Figures 6C and 7C) and 
HMGB1 (Figure  7D) in LPS-primed BMDMs and J774A.1 
cells, respectively. Without ATP treatment, compound C or 
compound C plus metformin did not induce pyroptosis in 
these two macrophage types (Figures S1C,D in Supplementary 
Material).
To further confirm the pharmacological data, we performed 
further experiments in J774A.1 cells in which the expression 
of AMPKα had been genetically knocked down by AMPKα1-
specific siRNA. When AMPKα expression was nearly reduced 
by 65% after siRNA knockdown (Figures 8A,B), the release of 
HMGB1 (Figures 8A,C, western blotting) and IL-1β (Figure 8D, 
CBA assay) by ATP or metformin plus ATP treatment was sig-
nificantly reduced as compared to that of NC siRNA treated cells. 
Consistent with the reduction of these inflammasome activation 
markers, ATP-induced pyroptosis was also significantly decreased 
(Figures 8E,F). Notably, metformin-mediated augmentation of 
pyroptosis by ATP stimulation was also markedly attenuated by 
AMPKα knockdown (Figures 8E,F). Taken together, these results 
indicated that AMPK signaling had contributed to ATP-induced 
inflammasome activation and pyroptosis in LPS-primed murine 
macrophages.
Metformin administration aggravates 
Mouse Bacterial sepsis
Finally, we investigated whether metformin administration 
enhanced systemic inflammation in vivo using a mouse model 
of bacterial sepsis. Mice were first intraperitoneally injected 
with a sublethal dose of live E. coli according to previous studies 
(9, 27). The bacterial infection at a dose of 1 × 109 CFU/mouse 
caused only ~10% mortality in the mice treated with vehicle 
after 24 h, but metformin administration accelerated the onset 
of death (within 24 h) and significantly increased the mortality 
of the mice to ~50% during the period of 4-day observation 
(Figure 9A), suggesting that metformin exacerbated the severity 
of bacterial sepsis. Consistent with this result, histopathological 
analysis showed that bacterial infection led to infiltration of 
inflammatory cells in the liver in both metformin and vehicle 
groups, but the mice in the metformin group showed more 
inflammatory cell infiltration and tissue injury around their 
hepatic vascular walls (Figure 9B). In further support of this, 
FigUre 6 | Pharmacological blockade of aMP-activated protein kinase signaling suppressed adenosine triphosphate (aTP)− or aTP+ metformin-
induced pyroptosis in mouse bone marrow-derived macrophages (BMDMs). BMDMs were first primed with lipopolysaccharide (500 ng/ml) for 4 h, and then 
pretreated with compound C (20 µM in Opti-MEM) for 1 h and metformin (2 mM in Opti-MEM) for 1 h. Subsequently, 2 mM ATP was added to the medium for 
30 min. (a) Pyroptotic cells were revealed by their fluorescence of propidium iodide (PI) (red) staining. The images of PI and Hoechst 33342 (blue; for all cells) 
staining were merged with bright-field images. Scale bar, 50 µm; Met, metformin. (B) Pyroptosis ratios were calculated by the number of PI-positive cells relative to 
the total number of cells in five random fields each containing about 100 cells. Data are shown as mean ± SD (n = 5). (c) The levels of soluble interleukin-1β in the 
cell culture supernatants were evaluated by cytometric bead array assay. Data are shown as mean ± SD (n = 3). One representative experiment from three 
independently performed experiments with similar results is shown. (D) The subcellular distribution of ASC (red) was revealed by immunofluorescence microscopy 
with the nuclei being stained with Hoechst 33342 (blue). Scale bar, 20 µm. (e) The ratios of cells containing ASC specks were calculated by the number of cells with 
ASC specks relative to the total number of cells from five random fields (each containing about 50 cells). Data are shown as mean ± SD (n = 5). One experiment of 
two independently performed experiments with similar results is shown. *P < 0.05; **P < 0.01; and ***P < 0.001.
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metformin-treated mice had a marked increase in their serum 
levels of IL-1β at 4-h and 8-h time points when compared with 
controls (vehicle treated) (Figure  9C), indicating increased 
inflammasome activation in metformin-treated mice upon 
bacterial infection. In addition, the percentages of neutrophils 
(CD11b+Gr-1+ cells) in the peritoneal cavity were greatly 
increased in metformin-treated mice in comparison to vehicle 
(Figures 10A,B). As indicators of inflammasome activation and 
pyroptosis (10), hepatic mature IL-1β and active caspase-1p10 
protein levels were higher in the metformin group as compared 
to control and vehicle group, as revealed by western blotting 
(Figures 10C–E). These results suggested that bacterial infec-
tion had systemically induced inflammasome activation and 
IL-1β maturation, and that metformin treatment enhanced 
such inflammasome activation and organ injury, culminating in 
aggravated bacterial sepsis in mice.
FigUre 7 | Pharmacological blockade of aMP-activated protein kinase signaling suppressed adenosine triphosphate (aTP)− or aTP+ metformin-
induced pyroptosis in J774a.1 cells. J774A.1 cells were first primed with lipopolysaccharide (LPS) (500 ng/ml) for 4 h, and then pretreated with compound C 
(20 µM in Opti-MEM) for 1 h and metformin (2 mM in Opti-MEM) for 1 h. Subsequently, 3 mM ATP was added to the medium for 30 min. (a) Pyroptotic cells were 
revealed by their fluorescence of propidium iodide (PI) (red) staining and the nuclei were stained with Hoechst 33342 (blue, for all cells). The images of PI and 
Hoechst 33342 staining were merged with bright-field images. Scale bar, 50 µm; Met, metformin. (B) Pyroptosis ratios were calculated by the number of PI-positive 
cells relative to the total number of cells in five random fields each containing about 100 cells. Data are shown as mean ± SD (n = 5). (c) The levels of soluble 
interleukin-1β in the supernatants were evaluated by cytometric bead array assay (n = 3). (D) Soluble HMGB1 in the culture supernatants were precipitated and 
evaluated by western blotting, setting the blot gray value of LPS + ATP group as 1.0 (n = 3). *P < 0.05 and ***P < 0.001.
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DiscUssiOn
During bacterial infection or tissue damage, ATP is released from 
the intracellular compartments of both the host and bacterial cells 
into the extracellular milieu (9, 33, 34). The extracellular ATP, 
acting as a second signal for canonical NLRP3 inflammasome 
activation, induces pyroptosis in innate immune cells including 
macrophages (6). However, the signaling pathways regulating the 
pyroptosis are largely unknown, although some of which have 
been uncovered recently (22, 35). In this study, we provided several 
lines of evidence to reveal that AMPK signaling regulated ATP-
induced inflammasome activation and pyroptosis in LPS-primed 
murine macrophages. First, ATP treatment has been shown to 
activate AMPK in LPS-primed macrophages by previous stud-
ies (21, 22) and ours. Augmentation of AMPK signaling by its 
agonist (metformin) robustly enhanced ATP-induced pyroptosis. 
Second, pharmacological blockade of AMPK activity by its inhibi-
tor (compound C) not only suppressed ATP-induced pyroptosis, 
but also mitigated the augmentation effect of metformin on the 
pyroptosis. Third, genetic knockdown of AMPKα, the kinase 
subunit of AMPK, also attenuated ATP-induced pyroptosis either 
with or without metformin treatment. Finally, in vivo adminis-
tration of metformin increased the systemic levels of IL-1β and 
hepatic inflammation in bacterial infected mice. Therefore, 
AMPK signaling had been involved in regulating ATP-induced 
inflammasome activation and pyroptosis.
One interesting phenomenon is that AMPK is suppressed 
in macrophages when stimulated with LPS or other inflam-
matory stresses (28), but it is sharply switched to an activated 
state when the cells are exposed to a second danger signal (e.g., 
FigUre 8 | Knockdown of AMPKα1 expression attenuated adenosine triphosphate (aTP)-induced pyroptosis. The expression of AMPKα1 in J774A.1 
cells were knocked down by small-interfering RNA (siRNA) targeting AMPKα1 gene. Negative control (NC) siRNA was recruited as a knockdown control. Seventy-
two hours after knockdown, the cells were primed with lipopolysaccharide (LPS) (500 ng/ml) for 4 h, followed by incubation with metformin (2 mM) for 1 h prior to 
ATP (3 mM) stimulation for 30 min. (a) The expression of AMPKα after knockdown was detected by western blotting. β-Tubulin was used as loading control. 
(B) Quantitative analysis of AMPKα levels relative to that of β-tubulin in western blotting (a). (c) The soluble HMGB1 levels were precipitated and evaluated by 
western blotting (a), setting the blot gray value of LPS + ATP group as 1.0. (D) The soluble interleukin-1β in the supernatants of each treatment group was 
evaluated by cytometric bead array assay (n = 3). *P < 0.05; **P < 0.01; and ***P < 0.001. (e) Pyroptotic cells were revealed by their fluorescence of propidium 
iodide (PI) (red) staining in conjunction with Hoechst 33342 (blue) staining (for all cells). The images of PI and Hoechst 33342 fluorescence were merged with 
bright-field images. Met, metformin. (F) Pyroptosis ratios were calculated by the number of PI-positive cells relative to total number of cells in five random fields each 
containing about 100 cells. Data are shown as mean ± SD (n = 5). Scale bars, 50 µm. ***P < 0.001.
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FigUre 9 | Metformin administration aggravated bacterial sepsis in mice. C57BL/6 mice were intraperitoneally injected with viable Escherichia coli at a dose 
of 1 × 109 CFU/mouse. After 1 h, the mice were intragastrically given with metformin at a dose of 250 mg/kg body weight or vehicle. (a) Kaplan–Meier survival 
curves of the mice monitored every 6 h for 4 days. Each group contained 10 mice and three independent experiments were performed with one set of data 
presented. *P < 0.05. (B) Histopathological analysis of liver sections after bacterial infection. Red arrows indicated the infiltrated inflammatory cells. (c) Serum 
interleukin-1β levels after bacterial infection. Data are shown as mean ± SD (n = 5). Each group contained five mice and two independent experiments were 
performed with one set of data presented. Scale bar, 50 µm. ***P < 0.001 and ns, not significant.
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ATP) (22). The cause for this sharp switch is still unknown. 
AMPK is a key regulator of cellular energy metabolism (36). 
Under nutritional and other cellular stresses, AMPK is acti-
vated and thus inhibits the mechanistic target of rapamycin 
complex 1 (mTORC1) activity via phosphorylation of Raptor 
(a component of mTORC1) or TSC2 (a suppressor of mTORC1) 
leading to the down-regulation of protein synthesis (37, 38). It 
also phosphorylates and thus inactivates acetyl-CoA carboxy-
lase (39), which catalyzes the carboxylation of acetyl-CoA to 
provide malonyl-CoA for the biosynthesis of fatty acids (40). 
Hence, the biosynthesis of cellular components including pro-
teins and lipids is suppressed upon AMPK activation (41). As a 
key regulator of energy metabolism, AMPK is likely involved in 
regulating such remarkable energy changes during the process 
of pyroptosis. Indeed, we found in this study that the AMPK 
signaling could regulate ATP-induced inflammasome activa-
tion and pyroptosis.
Pyroptosis is one critical consequence of ATP-induced 
inflammasome activation. During this process, several kinds of 
membranous channels or pores can be opened or formed in the 
cell membrane, allowing the release of intracellular contents (11). 
Mechanistically, ATP induces inflammasome activation mainly 
through its action on cell membrane receptor P2X7R (42, 43). 
After ATP engagement, P2X7R molecules form a non-selective 
cation channel for efflux of K+ ion. If P2X7R is persistently acti-
vated, it may further recruit pannexin-1 to form pores that allow 
IL-1β release (44–46) and induction of cell death. Importantly, 
ATP-induced K+ efflux can trigger NLRP3 inflammasome 
FigUre 10 | Metformin administration exacerbated inflammatory responses in bacterial sepsis. C57BL/6 mice were treated as described in Figure 9. 
(a,B) Flow cytometric analysis of neutrophils (CD11b+Gr-1+) in the peritoneal cavity after bacterial infection. Representative dot-plots are shown in (a) and 
histograms are shown in (B) as mean ± SD (n = 5). ***P < 0.001. (c–e) Western blot analysis of protein expression in the liver 8 h after the mice being infected with 
bacteria. The blots of three individual mice in each group were displayed (c). The relative protein levels of active caspase-1p10 (D) and mature interleukin-1β 
(e) were quantified by densitometry. Data are shown as mean ± SD (n = 5). *P < 0.05 and ns, not significant.
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assembly, leading to caspase-1 activation. The latter consequently 
cleaves gasdermin D to produce its N-terminal fragment, which 
forms another type of membrane pores to induce pyroptosis 
(47–49). The resultant pores have an inner diameter around 
32 nm (48), thus allowing the export of mature IL-1β, HMGB1, 
and other cellular components (50). It is hypothesized that the 
channel opening or pore-forming induced by extracellular ATP 
is regulated by AMPK signaling. Supporting this, ATP-triggered 
P2X7R can integrate PI3K/AKT and AMPK-mTOR signaling 
pathways to induce cell death in tumor cells (51). In line with 
this, our preliminary observation also revealed a decrease in the 
mTORC1 activity during the process of ATP-induced pyroptosis 
(data not shown), concomitant with the AMPK activation. In 
addition, AMPK signaling has been reported to trigger a rapid 
redistribution of intracellular GLUT4 onto the cell membrane 
and thus facilitate glucose uptake (52, 53). However, our pre-
liminary experiments showed that the distribution of P2X7R on 
the cell membrane upon ATP stimulation was not enhanced by 
AMPK agonist metformin treatment, at least in BMDMs (data 
not shown), suggesting additional mechanisms may be involved 
in this process.
Beyond P2X7R, NLRP3 is a critical component mediating the 
activation of caspase-1 and thus pyroptosis upon ATP treatment. 
The activity of NLRP3 is regulated by phosphorylation. Once 
dephosphorylated at tyrosine 861 by tyrosine phosphatase non-
receptor 22 (PTPN22), NLRP3 is activated to allow caspase-1 
activation and IL-1β release (35). It has also been revealed that 
mTORC1 signaling could regulate NLRP3 inflammasome activa-
tion in macrophages by upregulation of hexokinase-1-dependent 
glycolysis (22). As we found no significant change in the NLRP3 
protein levels upon AMPK activation by metformin, it is likely 
that AMPK regulates the phosphorylation of NLRP3 directly or 
indirectly through other kinases or phosphatases like PTPN22. 
More research is thus warranted to reveal the precise mechanism 
of AMPK signaling in regulating NLRP3 inflammasome activa-
tion and pyroptosis.
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Metformin is a first-line drug for type 2 diabetes (T2D). As 
an AMPK agonist (32), metformin has been demonstrated to 
suppress both hepatic gluconeogenesis and lipid genesis (54, 55) 
in patients with obesity and T2D or animal models. Nonetheless, 
the exact mechanism underlying the action of metformin on 
obesity and diabetes is still not completely understood. NLRP3 
inflammasome activation is upregulated in T2D patients (56) 
and a previous work has demonstrated that NLRP3 expression in 
adipose tissues impairs insulin-sensitivity (13). However, spon-
taneous pyroptosis among these activated cells may be limited. 
Instead, the AMPK activity is inhibited in patients with obesity 
and T2D and their tissue-resident macrophages are activated 
(57). These macrophages continuously release inflammatory 
cytokines to contribute to and maintain the chronic inflam-
matory diseases (58–60). Based on these findings and ours, we 
propose a possibility that metformin may provide beneficial 
effect to T2D patients by promoting pyroptosis to eliminate the 
chronically activated macrophages, particularly those in adipose 
tissues, thus finally alleviating the chronic inflammation in T2D 
patients.
Our data appeared inconsistent with some previous studies, 
which showed that metformin treatment suppressed intracel-
lular levels of pro-IL-1β without influencing IL-1β secretion 
(61) or reduced IL-1β and IL-18 secretion (56). This discrepancy 
between the results of those previous studies and ours may be due 
to different experimental settings (61) or recruitment of different 
cellular models (56). Although previous reports have shown that 
another AMPK agonist AICAR (at a low dose of 100 µM) does 
not influence LPS + ATP-induced IL-1β secretion (22, 59), higher 
doses of AICAR may show different effects. Indeed, we found that 
a high dose of AICAR (2 mM, a commonly used concentration 
to activate AMPK) had similar effects as metformin did on ATP-
induced pyroptosis in J774A.1 cells (data not shown).
In summary, our study revealed a link between AMPK 
signaling and ATP-induced pyroptosis in LPS-activated mac-
rophages. Enhancing AMPK activity could significantly aug-
ment ATP-induced inflammasome activation and pyroptosis in 
macrophages, leading to increased release of IL-1β and HMGB1. 
Our finding may be of significance on investigating new AMPK-
targeting therapies for diseases involving inflammasome activa-
tion, including obesity, diabetes, and bacterial sepsis.
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